Q4 2025 Vaxart Inc Earnings Call Transcript
Key Points
- Vaxart Inc (VXRT) established a partnership with Dynavax for their oral COVID-19 vaccine candidate, receiving a $25 million upfront payment and a $5 million equity investment.
- The partnership with Dynavax, now a Sanofi company, provides significant validation of Vaxart's oral vaccine platform.
- Vaxart published a complete data set from the clinical study of their oral norovirus vaccine candidate in lactating mothers, demonstrating safety and immunogenicity.
- The company managed to reduce operating costs by entering into a lease termination agreement, enhancing their ability to focus financial resources on advancing lead programs.
- Vaxart reported a significant increase in revenue for the full year 2025, reaching $237.3 million compared to $28.7 million in 2024, primarily due to contracts related to BARDA and the Dynavax agreement.
- There is a slight delay in reporting the 400-person sentinel cohort data for the COVID-19 vaccine trial, now expected in early second quarter of 2026 instead of late first quarter.
- The 400-person sentinel cohort was designed primarily for safety assessment, not efficacy, limiting immediate insights into the vaccine's effectiveness.
- The larger 5,000-subject KP.2 cohort data, which will provide efficacy insights, is not expected until late in the fourth quarter of 2026.
- Vaxart's continuation of the norovirus program is contingent on securing a partnership or other funding, indicating potential financial constraints.
- The company remains dependent on strategic partnerships and non-dilutive funding options to extend their cash runway, highlighting ongoing financial challenges.
Greetings and welcome to the Vaxart fourth quarter business update and year-end 2025 financial results conference call. A question-and-answer session will follow management's opening remarks. (Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel. Thank you. You may begin.
Good afternoon, and welcome to today's call. Joining us from Vaxart are Steven Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; James Cummings, Chief Medical Officer; and Jeroen Grasman, Chief Financial Officer.
Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
